Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. Th…

Biotechnology

US, San Diego [HQ]

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Major Shareholders · Proxy Ben. Owners

Shareholders

Major Shareholders · Structure

Breakdown

The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. can't present any analysts estimates at the moment detail analysis.

Intraday

Shares Outstanding

551,281,000

Volume

6,933

Volume on Avg.

318,945

Beneficial Owners Beta

Beneficial owners who control a significant portion of the shares outstanding.

SEC Source

Form 3/4/5

Owner	Shares	Equivalence - $0.00 per share	Last Form/Filing	Last Transaction
10% Holder
	5,050,427	$0	10/05/23
Officers/Directors Below 10%
Ji Henry Internal : President, CEO and Chairman of the Board of Directors	20,000	$0	03/20/23	X 19,500 x $0.80 = $15,600.00
Janda Kim Internal : Director	4,900	$0	04/15/21	M 1,900 x $3.50 = $6,650.00
Czerepak Elizabeth Internal : EVP & Chief Financial Officer	0	$0	11/18/21	0 x $0 = $0
Reilly Tammy Internal : Director	0	$0	05/20/22	0 x $0 = $0
Smith Robin L Internal : Director	135,000	$0	09/03/21	M 75,000 x $3.95 = $296,250.00
Wu Yue Alexander Internal : Director	0	$0	08/30/21	0 x $0 = $0
Shah Jaisim Internal : Director	0	$0	08/30/21	0 x $0 = $0
Lemus David Internal : Director	0	$0	06/15/20	0 x $0 = $0
Followwill Dorman Internal : Director	0	$0	08/30/21	0 x $0 = $0
Asghar Najjam Internal : Chief Financial Officer	0	$0	11/13/20	0 x $0 = $0
Shao Jiong Internal : Chief Financial Officer	0	$0	06/15/20	0 x $0 = $0
Lee Edgar Internal : Director	0	$0	06/15/20	0 x $0 = $0